Kolexia
Moreau Philippe Hématologie
Moreau Philippe
Hématologie
Hôpital Hôtel-Dieu Nantes
Nantes, France
1.5 K Activités
24 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Myélome multiple Tumeurs à plasmocytes Récidive tumorale locale Maladie résiduelle Lymphomes Leucémies Tumeurs hématologiques Aberrations des chromosomes Maladie du greffon contre l'hôte

Collaborateurs

Voir plus
Facon Thierry
Facon Thierry
Hôpital Huriez, Lille, France
Avet-Loiseau Herve
Avet-Loiseau Herve
Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
Leleu Xavier
Leleu Xavier
Hôpital La Miletrie, Poitiers, France
Touzeau Cyrille
Touzeau Cyrille
Hôpital Hôtel-Dieu Nantes, Nantes, France

Industries

Voir plus
Janssen
196 collaboration(s)
Dernière en 2023
Sanofi
52 collaboration(s)
Dernière en 2023
GSK
32 collaboration(s)
Dernière en 2023
Amgen
30 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma: A Phase 3 Randomized, Multicenter Study of Subcutaneous vs. Intravenous Administration of Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma
Essai Clinique (Janssen)   11 mars 2024
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma: An Open-Label, Multicenter, Phase 1b Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Regimens for the Treatment of Subjects With Multiple Myeloma
Essai Clinique (Janssen)   11 mars 2024
Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma: Phase 3 Study Comparing Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Subjects With Relapsed or Refractory Multiple Myeloma
Essai Clinique (Janssen)   11 mars 2024
Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma.
Nature communications   06 mars 2024
Correction: GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review.
Blood cancer journal   06 mars 2024
Adjusting for subsequent therapies in the TOURMALINE-MM1 study shows clinically meaningful improvement in overall survival with addition of ixazomib to lenalidomide and dexamethasone.
Haematologica   29 février 2024
MonumenTAL-1: A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma
Essai Clinique (Janssen)   27 février 2024
Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma: A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy
Essai Clinique (Janssen)   27 février 2024
MoMMent: A Prospective, Multinational Study of Real-Life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma
Essai Clinique (Janssen)   27 février 2024
A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma: A Randomized Phase 2 Trial to Evaluate Three Daratumumab Dose Schedules in Smoldering Multiple Myeloma
Essai Clinique (Janssen)   27 février 2024